Humira biosimilar market remains stagnant, with AbbVie losing only 2% of market share, Samsung report shows

Ab­b­Vie is show­ing off to the world how it’s main­tain­ing most of the sales vol­ume for the Hu­mi­ra (adal­i­mum­ab) fran­chise in the US, los­ing just 2% of mar­ket share since sev­er­al biosim­i­lars launched in Ju­ly, ac­cord­ing to a new Sam­sung Bioepis biosim­i­lars re­port.

The biosim­i­lar mar­ket for Hu­mi­ra has re­mained stag­nant, even with new en­trants and low­er prices. Three of the nine Hu­mi­ra biosim­i­lars cur­rent­ly mar­ket­ed are priced about 85% less than Hu­mi­ra’s whole­sale ac­qui­si­tion cost (WAC).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.